A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG‐asparaginase, and doxorubicin

Abstract

The VXLD with metformin was tolerable with a RP2D for metformin of 1,000 mg/m² /day and yielded responses in a heavily pretreated population. ER stress was induced and toxicities attributable to metformin occurred in all dose levels.